No consistency in endophthalmitis prophylaxis

Article

Methods of attempting to prevent postoperative endophthalmitis vary widely across the United Kingdom, according to a study published in the May 2008 issue of Eye.

Methods of attempting to prevent postoperative endophthalmitis vary widely across the United Kingdom, according to a study published in the May 2008 issue of Eye.

Patel Gordon-Bennett of the department of ophthalmology at Hinchingbrooke Hospital, Cambridgeshire, UK and colleagues conducted a telephone interview survey with 800 staff from ophthalmic training units across the UK between October and November 2005.

The team found that 99.4% of surgeons (n=795) used a preoperative preparation of povidone-iodine on the skin; 69.8% (n=558) instilled povidone-iodine into the conjunctival sac; and 5.9% (n=47) administered antibiotic eyedrops. During surgery, 17.8% (n=142) administered intracameral antibiotics: 66.4% (n=531) administered subconjunctival cefuroxime, 6.0% (n=48) administered routine gentamycin and 4.9% (n=39) administered alternative subconjunctival antibiotics; 16.8% (n=134) administered topical drops as a single dose. Combination steroid/neomycin drops were used by 64.4% of surgeons (n=515) postoperatively; 26.6% (n=213) administered separate drops.

The study revealed wide variation in the preventative measures employed by surgeons. The most frequently deployed methods of endophthalmitis prophylaxis are administrations of subconjunctival and intracameral cefuroxime.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.